Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor-positive Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: EP0062
Sponsor: Ellipses Pharma